MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

Completed
Conditions
Pure Red-cell Aplasia
Interventions
First Posted Date
2005-09-21
Last Posted Date
2013-04-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
124
Registration Number
NCT00211068

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

Completed
Conditions
Pure Red-cell Aplasia
Interventions
Other: No intervention
First Posted Date
2005-09-21
Last Posted Date
2013-04-30
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
52
Registration Number
NCT00211042

A Study to Observe the Causes and Treatment of Anemia in Critically Ill Children

Completed
Conditions
Anemia
First Posted Date
2005-09-21
Last Posted Date
2013-04-16
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1201
Registration Number
NCT00211055

An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.

Phase 3
Completed
Conditions
Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
142
Registration Number
NCT00210860

A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation

Completed
Conditions
Erectile Dysfunction
Interventions
Behavioral: No intervention
First Posted Date
2005-09-21
Last Posted Date
2012-10-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1115
Registration Number
NCT00210678

An Open Label Extension of a Study of Topiramate in Chronic Migraine.

Phase 3
Completed
Conditions
Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
200
Registration Number
NCT00210873

A Pilot Study of Topiramate in Childhood Absence Epilepsy

Phase 2
Completed
Conditions
Epilepsy, Absence
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
12
Registration Number
NCT00210574

A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.

Phase 3
Completed
Conditions
Urinary Tract Infections
Pyelonephritis
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1109
Registration Number
NCT00210886

The Duration Study

Phase 3
Terminated
Conditions
Anemia
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
2
Registration Number
NCT00210730
© Copyright 2025. All Rights Reserved by MedPath